Ozempic receives FDA nod for treating chronic kidney disease

Ozempic Receives New Indications in Chronic Kidney Disease
Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with chronic kidney disease.
Ozempic Approval Expanded to Include T2D Patients With Chronic Kidney Disease
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
FDA approves Ozempic to help reduce risk of worsening chronic kidney disease
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of
This country approves Ozempic to reduce risk of kidney disease in diabetes patients
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing kidney failure risk, disease progression, and death due to heart problems in diabetes patients with chronic kidney disease. This approval marks Ozempic as the first GLP-1 treatment option for type 2 diabetes and chronic kidney disease,
FDA approves Ozempic for kidney disease treatment in diabetes patients
The U.S. Food and Drug Administration (FDA) has granted approval for an expanded use of Ozempic® (semaglutide) injection, developed by pharmaceutical company Novo Nordisk (NYSE:NVO). The medication is now approved to lessen the risk of kidney disease progression,
US FDA clears Ozempic for use in diabetics with chronic kidney disease: What does it mean for you?
It showed that 1 mg Ozempic led to a 24 per cent reduced risk of worsening kidney disease and kidney failure (end-stage kidney disease)
FDA Approves Novo Nordisk’s Ozempic to Reduce Kidney Disease in Patients with Type 2 Diabetes, Chronic Kidney Disease
Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney disease, kidney failure, and cardiovascular death in patients treated with Ozempic.
FDA Approves Ozempic in Chronic Kidney Disease
The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in kidney function, or death from kidney or heart causes, in diabetic patients with chronic kidney disease.
FDA Approves Ozempic to Reduce Kidney Disease in Type 2 Diabetes
Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common complication of type 2 diabetes.
Novo Nordisk’s Ozempic granted FDA approval in chronic kidney disease
Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of kidney disease worsening, kidney failure and cardiovascular disease (CVD) death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD).
RTE Online1d
'Profound vomiting' after Ozempic led to Cork woman's death
An inquest in Cork has been told that a 66-year old woman died from "profound vomiting" brought on by the drug Ozempic, which ...
Impacts5d
What is Ozempic injection and how does it works?
When it comes to losing fat without extreme exercise, only a few medicines are worth considering. With the innovation in the medical world, physicians are now recommending the Ozempic weight loss ...